Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01BYB
|
||||
| Former ID |
DAP000474
|
||||
| Drug Name |
Adenosine triphosphate
|
||||
| Synonyms |
ATP; Adenosinetriphosphate; Adenosintriphosphorsaeure; Adenylpyrophosphate; Adephos; Adetol; Adynol; Atipi; Atriphos; Cardenosine; Fosfobion; Glucobasin; Myotriphos; Phosphobion; Striadyne; Triadenyl; Triphosaden; Triphosadenine; Triphosphaden; Adenylpyrophosphoric acid; Triphosphoric acid adenosine ester; H4atp; ATP (nucleotide); Adenosine-triphosphate; Ara-ATP; Triphosadenine (DCF); Adenosine 5'-triphosphate; Adenosine 5'-triphosphoric acid; Adenosine 5'-(tetrahydrogen triphosphate); Adenosine-5'-triphosphate; Adenosine 5'-triphosphate(4-); Adenosine, 5'-(tetrahydrogen triphosphate); Ado-5'-P-P-P; [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate; [[[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate; [[[(2R,3S,4R,5R)-5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid; 3b2q; 5'-Atp; 5-(6-Aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-ylmethoxy-hydroxy-phosphoryloxy-hydroxy-phosphoryl oxyphosphonic acid; 9-beta-D-Arabinofuranosyladenine 5'-triphosphate; 9H-purin-6-amine, 9-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Dietary shortage [ICD9: 260-269; ICD10:E40-E46] | Approved | [536838] | ||
| Therapeutic Class |
Dietary supplement
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C10H12N5O13P3-4
|
||||
| Canonical SMILES |
C1=NC2=C(C(=N1)N)N=CN2C3C(C(C(O3)COP(=O)([O-])OP(=O)([O<br />-])OP(=O)([O-])[O-])O)O
|
||||
| InChI |
1S/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/p-4/t4-,6-,7-,10-/m1/s1
|
||||
| InChIKey |
ZKHQWZAMYRWXGA-KQYNXXCUSA-J
|
||||
| CAS Number |
CAS 56-65-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
2157, 8148096, 11688362, 24877532, 39443564, 49737792, 50247497, 53812597, 53812679, 53812681, 53812739, 53812902, 53812904, 56412694, 56436522, 60849405, 84970651, 85145927, 87557452, 87557505, 87557712, 104075349, 114001216, 131319136, 137251856, 164151282, 170481218, 170481265, 170481338, 170481406, 170481407, 170481627, 170481825, 170482177, 170482179, 170482197, 170482263, 170483168, 170483402, 170483906, 170483907, 170484256, 170485046, 170485047, 170485048, 223501249
|
||||
| ChEBI ID |
ChEBI:15422
|
||||
| Target and Pathway | |||||
| Target(s) | Proto-oncogene c-Abl | Target Info | Inhibitor | [535436], [536557] | |
| PANTHER Pathway | Axon guidance mediated by Slit/Robo | ||||
| Pathway Interaction Database | p73 transcription factor network | ||||
| ATM pathway | |||||
| Regulation of Telomerase | |||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| Lissencephaly gene (LIS1) in neuronal migration and development | |||||
| PDGFR-beta signaling pathway | |||||
| Neurotrophic factor-mediated Trk receptor signaling | |||||
| Validated transcriptional targets of TAp63 isoforms | |||||
| p53 pathway | |||||
| Regulation of retinoblastoma protein | |||||
| Reactome | Regulation of actin dynamics for phagocytic cup formation | ||||
| CDO in myogenesis | |||||
| RHO GTPases Activate WASPs and WAVEs | |||||
| HDR through Single Strand Annealing (SSA) | |||||
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| WikiPathways | Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Fcgamma receptor (FCGR) dependent phagocytosis | |||||
| ATM Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Pathogenic Escherichia coli infection | |||||
| Regulation of Microtubule Cytoskeleton | |||||
| Integrated Breast Cancer Pathway | |||||
| Signaling by Robo receptor | |||||
| Myogenesis | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| References | |||||
| Ref 535436 | High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 2002 May 1;99(9):3472-5. | ||||
| Ref 536557 | Targeted chronic myeloid leukemia therapy: Seeking a cure. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S9-15. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.